🔗 Share this article

As America proceeds with sweeping changes to its immunization schedules, a particular individual appears unexpectedly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about coronavirus vaccines during the global health crisis and has zeroed in on alleged fatalities following Covid vaccination in her short position at the FDA.

Planned Changes to Childhood Immunization Program

Public health authorities had intended to unveil major revisions to the pediatric vaccination calendar in December, aligning the US with the Danish national calendar, it is understood – a major change that would put the US out of alignment with many the international standard with insufficient data for public health gain. The announcement has been postponed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to present at the meeting. She was newly appointed acting director of the FDA’s CDER, the fifth person to lead the center this year.

A Shift at the Agency

This interim role might represent a strengthened alliance between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for ending certain pediatric vaccine recommendations in the US to become more similar to Denmark's approach, a society with universal health coverage and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

Dr. Høeg has no obvious experience in drug development, oversight or leadership, which has been customary for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She has no expertise in pharmaceutical oversight.”

Former commissioners of the center would “understand laws and regulations and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an enormous workload at the agency, Woodcock stated.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and other areas, and every single one need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a substantial management component to the role, which supervises more than 5,000 employees. “It is a huge management job, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Initiatives

Regarding questions about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among agency officials on vaccines, a spokesperson stated that the “questions rely on incorrect assumptions”.

“Her resume aligns with the responsibilities of her position,” the spokesperson explained, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious expedited therapy clearance system that reportedly troubled her preceding directors. “By what process are these drugs being picked for this voucher program? Who is making the choices?” Dr. Howard questioned. “There is a lot of secrecy happening at the FDA right now.”

Overall, he said, “the agency looks to be trending towards laxer regulations of pharmaceuticals, aside from shots.”

Documented Past Work on Immunizations

With vaccines, Høeg has a clearer, if concerning, history, some experts observe. She released a study using unverified public submissions to estimate the frequency of myocarditis following Covid immunization. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to indicate Covid vaccinations are riskier than they are.

Included in her “desired changes” for the current administration included altering guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Høeg has allegedly floated the idea of barring young men from obtaining Covid vaccinations.

“She’s an complete true believer who commences with her beliefs and works backwards to fit the evidence in a highly misleading, fraudulent fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|